8 results about "Platlet-Derived Growth Factor" patented technology

The invention discloses a serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition and application thereof. The serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition is prepared from the following components in parts by mass: 15 to 25 parts of platelet-derived growth factor-BB; 15 to 25 parts of basic fibroblast growth factors; 8 to 12 parts of transforming growth factor-beta; and 8-12 parts of recombinant human insulin. The serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition and the application thereof disclosed by the invention have the following beneficial effects: (1) the proliferation efficiency is remarkably improved; (2) the cell morphology and dryness can be well maintained; and (3) the compliance and the compatibility are good.

The present application relates to the technical field of freeze-dried powder, and in particular to a freeze-dried powder composition for hair regeneration and a preparation method thereof. The freeze-dried powder composition comprises 5-15 parts of vascular endothelial growth factor, 3-10 parts of platelet-derived growth factor, 1-5 parts of copper peptide, 0.5-3 parts of acetyl tetrapeptide-3, 2-8 parts of baicalein, 1-5 parts of asiaticoside, 20-40 parts of freeze-drying protectant, and 1-3 parts of nano-silicon dioxide. The preparation method comprises mixing the pretreated vascular endothelial growth factor, platelet-derived growth factor, copper peptide, acetyl tetrapeptide-3, baicalein, and asiaticoside with the freeze-drying protectant and nano-silicon dioxide, and then freeze-drying. The freeze-dried powder composition can promote the growth of hair, improve the microenvironment of the scalp, and provide long-lasting support for the healthy growth of hair. The preparation method improves the stability and biological activity of the active ingredients, and enhances the overall performance and safety of the product.

Modified platelet-derived growth factor receptor alpha (PDGFRα) polypeptides are described. The modified polypeptides include at least one amino acid substitution that allows the polypeptide to retain the capacity to bind a cytomegalovirus (CMV) trimer comprised of glycoprotein H (gH), gL and gO, but leads to reduced binding to one or more platelet-derived growth factor (PDGF) ligands. Use of the modified PDGFRα polypeptides for inhibiting CMV replication and / or spread, or treating a CMV infection, is also described.

This invention discloses a topical preparation of recombinant platelet-derived growth factor (PDGF) and its preparation method. In this invention, each milliliter of the topical preparation contains the following components and dosages: 40,000-85,000 IU of PDGF, 50-200 mg of polyvinyl alcohol, 10-100 mg of arginine hydrochloride, 54-60 mg of sodium chloride, 40-80 mg of disodium hydrogen phosphate, 0.5-2.5 mg of sodium dihydrogen phosphate, and 0.5-5 mg of benzalkonium chloride, diluted to 10 ml with water for injection. The pH of the solution is 7.0. The PDGF topical solution of this invention has optimized compatibility of its raw materials, exhibits good stability, and can promote wound healing effectively and rapidly, shortening wound healing time and improving wound healing efficiency, thus demonstrating good therapeutic efficacy.

The present disclosure provides methods for treating delayed union or nonunion fractures in a bone More specifically, the present disclosure provides methods of inducing bone formation in a delayed union or nonunion fracture in a bone comprising: applying to a site of delayed union or nonunion fracture a composition comprising a platelet-derived growth factor (PDGF) solution disposed in a biocompatible matrix.

The invention relates to the technical field of biomedical materials, and discloses an intelligent responsive degradable hydrogel, which is characterized by comprising the following components: a base material which is a blend of hyaluronic acid and chitosan and has a total concentration of 2.0%-3.0% w / v; the cross-linking agent is an anti-TNF-alpha monoclonal antibody, and the dosage of the cross-linking agent is 0.8 mu mol / g of the base material; the auxiliary cross-linking agent is genipin with the concentration of 0.1% w / v; the loaded drug is a platelet-derived growth factor, and the drug loading capacity is 100 ng / mg of the hydrogel. The hydrogel can specifically recognize an inflammation signal in a chronic wound high TNF-alpha microenvironment, trigger network degradation and synchronously release a repair promoting medicine, recognition-degradation-administration closed-loop regulation is achieved, and the hydrogel is suitable for diabetic foot ulcer and other hard-to-heal wounds.

The application provides a kind of osteochondral repair material and its preparation method and application, belong to the technical field of biomedical materials.The application is prepared hyaluronic acid-collagen with collagen as organic matrix, through the crosslinking reaction mediated by crosslinking agent;Hydroxyapatite is deposited in situ in the self-assembly process of collagen fiber through in vitro biomimetic mineralization technology, and mineralized collagen with different mineralization degrees is prepared;Iterative layered freeze-drying technology is used to construct biomimetic cartilage layer, calcification layer and subchondral layer in turn, and transforming growth factor-beta 3 and platelet-derived growth factor-BB are also loaded by physical adsorption to synergistically promote the repair and regeneration of osteochondral defects.The preparation process of the application is mild and controllable, and the prepared osteochondral repair material has good biocompatibility and intelligent active factor delivery function, and has important application prospect in the field of osteochondral tissue engineering and clinical defect repair.

Disclosed herein are compounds of formula (I) wherein X, L1, and HSA conjugate are as defined herein, methods of preparation thereof, and methods of using thereof for improving cardiac repair, particularly post infarct.